Dr. Abraham Chachoua on Anti-PD-1 and Anti-PD-L1 Treatments in Lung Cancer
Abraham Chachoua, MD, associate professor of Oncology, NYU Langone Medical Center, talks about the present use of anti-PD-1 and anti-PD-L1 becoming the standard second-line treatment in lung cancer.
Abraham Chachoua, MD, associate professor of Oncology, NYU Langone Medical Center, talks about the present use of anti-PD-1 and anti-PD-L1 treatments becoming the standard second-line treatment in lung cancer. He says that the treatments could become frontline treatments in the future, as single agents or in combination with other treatments, which is something researchers are currently working on.
Chachoua says one treatment in particular, nivolumab, was approved for squamous carcinoma and non-squamous carcinoma based on the CHECKMATE-057 trial. He adds that treatments like pembrolizumab were approved as well, though for patients that have PD-1 expression of greater than 50%. Chachoua said deciding who to test for PD-1 expression and who to give these treatments to is entirely up to the discretion of oncologists based on each individual patient.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
